Concizumab is a humanized monoclonal antibody that blocks tissue factor pathway inhibitor (TFPI), another natural anticoagulant protein, and increases thrombin production in hemophilia A and B Gene therapy using a harmless virus-associated delivery of either the factor VIII or IX gene is also in clinical trials for the treatment of hemophilia A or B (8).